Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway.
Department of Research and Innovation, Division of Mental Health and Addiction, Oslo University Hospital, Oslo, Norway; Department of Psychology, Faculty of Social Sciences, University of Oslo, Oslo, Norway.
Schizophr Res. 2024 Sep;271:91-99. doi: 10.1016/j.schres.2024.07.006. Epub 2024 Jul 16.
Data-driven classification of long-term psychotic symptom trajectories and identification of associated risk factors could assist treatment planning and improve long-term outcomes in psychosis. However, few studies have used this approach, and knowledge about underlying mechanisms is limited. Here, we identify long-term psychotic symptom trajectories and investigate the role of illness-concurrent cannabis and stimulant use.
192 participants with first-episode psychosis were followed up after 10 years. Psychotic symptom trajectories were estimated using growth mixture modeling and tested for associations with baseline characteristics and cannabis and stimulant use during the follow-up (FU) period.
Four trajectories emerged: (1) Stable Psychotic Remission (54.2 %), (2) Delayed Psychotic Remission (15.6 %), (3) Psychotic Relapse (7.8 %), (4) Persistent Psychotic Symptoms (22.4 %). At baseline, all unfavorable trajectories (2-4) were characterized by more schizophrenia diagnoses, higher symptom severity, and longer duration of untreated psychosis. Compared to the Stable Psychotic Remission trajectory, unstable trajectories (2,3) showed distinct associations with cannabis/stimulant use during the FU-period, with dose-dependent effects for cannabis but not stimulants (Delayed Psychotic Remission: higher rates of frequent cannabis and stimulant use during the first 5 FU-years; Psychotic Relapse: higher rates of sporadic stimulant use throughout the entire FU-period). The Persistent Psychosis trajectory was less clearly linked to substance use during the FU-period.
The risk for an adverse long-term course could be mitigated by treatment of substance use, where particular attention should be devoted to preventing the use of stimulants while the use reduction of cannabis may already yield positive effects.
基于数据的长期精神病症状轨迹分类和相关风险因素的识别,可以辅助治疗计划制定,并改善精神病的长期预后。然而,很少有研究采用这种方法,而且对潜在机制的了解有限。在此,我们确定了长期精神病症状轨迹,并研究了并发的精神活性物质(包括大麻和兴奋剂)使用的作用。
192 名首发精神病患者在 10 年后接受了随访。使用增长混合建模估计精神病症状轨迹,并检验基线特征与随访期间(FU)大麻和兴奋剂使用之间的关联。
共出现 4 种轨迹:(1)稳定精神病缓解(54.2%),(2)延迟精神病缓解(15.6%),(3)精神病复发(7.8%),(4)持续精神病症状(22.4%)。基线时,所有不利轨迹(2-4)的特点是更多的精神分裂症诊断、更高的症状严重程度和更长的未治疗精神病持续时间。与稳定精神病缓解轨迹相比,不稳定轨迹(2、3)在 FU 期间与大麻/兴奋剂使用之间存在明显的关联,大麻存在剂量依赖性效应,但兴奋剂无此效应(延迟精神病缓解:FU 的前 5 年内频繁使用大麻和兴奋剂的比例较高;精神病复发:整个 FU 期间偶尔使用兴奋剂的比例较高)。持续精神病轨迹与 FU 期间的物质使用之间的联系不太明确。
通过治疗物质使用,可能减轻不良长期病程的风险,特别应注意预防使用兴奋剂,而减少大麻的使用可能已经产生积极影响。